Gastrinoma
15
0
2
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
3 terminated out of 15 trials
72.7%
-13.8% vs benchmark
0%
0 trials in Phase 3/4
75%
6 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
DOTATOC PET/CT for Imaging NET Patients
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Evaluating Patients With Abnormal Levels of Gastric Acid